Literature DB >> 12778165

The biology of VEGF and its receptors.

Napoleone Ferrara1, Hans-Peter Gerber, Jennifer LeCouter.   

Abstract

Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12778165     DOI: 10.1038/nm0603-669

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  2000 in total

1.  VEGF and VEGFR1 levels in different regions of the normal and preeclampsia placentae.

Authors:  Akriti S Sahay; Anjali T Jadhav; Deepali P Sundrani; Girija N Wagh; Savita S Mehendale; Preeti Chavan-Gautam; Sadhana R Joshi
Journal:  Mol Cell Biochem       Date:  2017-08-02       Impact factor: 3.396

2.  Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.

Authors:  Igor A Astsaturov; Neal J Meropol; R Katherine Alpaugh; Barbara A Burtness; Jonathan D Cheng; Sue McLaughlin; André Rogatko; Zhiheng Xu; James C Watson; Louis M Weiner; Steven J Cohen
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

3.  Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity.

Authors:  Steven J Budd; M Elizabeth Hartnett
Journal:  Arch Ophthalmol       Date:  2010-05

4.  Expression of Angiogenic Factors in Psoriasis Vulgaris.

Authors:  Lakshna Sankar; Dhanalakshmi Arumugam; Sudha Boj; Priyanka Pradeep
Journal:  J Clin Diagn Res       Date:  2017-03-01

Review 5.  Exploiting novel molecular targets in gastrointestinal cancers.

Authors:  Wen W Ma; Manuel Hidalgo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

6.  Inhibition of inflammasome activation improves the impaired pattern of healing in genetically diabetic mice.

Authors:  Alessandra Bitto; Domenica Altavilla; Gabriele Pizzino; Natasha Irrera; Giovanni Pallio; Michele R Colonna; Francesco Squadrito
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 7.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

Review 8.  Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Authors:  David S Boyer; J Jill Hopkins; Jonathan Sorof; Jason S Ehrlich
Journal:  Ther Adv Endocrinol Metab       Date:  2013-12       Impact factor: 3.565

9.  Lentivirus vector-mediated knockdown of erythropoietin-producing hepatocellular carcinoma receptors B4 inhibits laser-induced choroidal neovascularization.

Authors:  Jing Du; Wei Zhao; Yusheng Wang; Yan Cai
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-04       Impact factor: 2.671

Review 10.  Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.